Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23950590 | 1.00 | CES2 (0.57) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL21448670 | 1.00 | CES2 (0.57) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL21452468 | 1.00 | CES2 (0.57) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL3414312 | 0.98 | CES2 (0.54) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL15342883 | 0.93 | CES2 (0.46) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL10904395 | 0.91 | CA1 (0.57) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL11115354 | 0.91 | CA1 (0.57) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL10904396 | 0.91 | CA1 (0.57) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL31472637 | 0.91 | CES2 (0.57) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL28441934 | 0.91 | CES2 (0.57) | CES2MEN1FAAHMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323992-A1 | GEMCITABINE PRODRUGS | CURE BIOPHARMA INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323992-A1 | GEMCITABINE PRODRUGS | TYMP, PIK3CA, DCK | CES2 2830/4885MEN1 2740/4885FAAH 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.